



IDENTIFY NEW FUNDING Opportunities

In Cancer Drug Development



A Comprehensive Intelligence Report On **ONCOLOGY** DRUG 2013 FUNDING

REPORT COVERS 'ONCOLOGY FOCUSED'

- **321** Active Venture Capital Firm Profiles
Investment Size | Criteria | Geographic focus
- **502** Company Funding Details
Includes past 10 years all Major Investment Rounds/Series
- **947** Venture Partners Professional Profiles
Linkedin & Email IDs of Partners | Personal Assistants Email IDs / Contact details
- **3000+** Funding Round Details
Details of Series A | B | C | D | E | F Included
- **6 pages** Infographics Based Summary
Quick explore the Geographic distribution of VCs & their Geographic preference of funding w.r.t USA, Europe & Asia.

Full Coverage

Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage fundings. It brings more authentic data under evaluation and is designed in a manner to keep knowledge intact, clear and precise. It also offers quick navigation on past 10 years major investments in the domain, thus allowing the information on fingertips' and enhances your drug funding in-depth understanding. Further any information duplication is avoided to provide you with a clear and actionable intelligence.

Complete Cancer Drug Investors Intelligence

- One of the largest updated data available, covering 321 active cancer-focused investors with their investment details in more than 500 oncology-focused companies.
- Includes Active Venture Capital, Private Equity and some notable Angel Investor firms.
- Also includes individual Investor Company profile, their core oncology venture partner team details & Investor funding preferences & past investments.

Identify Top Investors

- With quick navigation tables, easily identify the top investors and their rich investment portfolio.
- Identify where large investors are investing in; and easily predict their funding preferences.
- Within oncology funding space, identify individual investor's inclination towards funding drugs, diagnostics or risky technologies.

All at One Place

- Worldwide coverage of 500+ companies including cancer drug discovery/development, cancer diagnostic and cancer device/technology companies.
- Past 10 years complete funding data including various follow-up funding round/series details.
- Navigation Table to identify various funding Exits; through IPO or M&A activities.
- Quick all sets of funding from Seed to Growth are covered.

*Largest Oncology Funding Database with
Oncology focused Venture Partner's Profiles.*



Report Structures

The complete 570 pages report is divided in three main sections for easy and quick navigation within report. Report sections contains thousands of interlinks to reach desired information on a single click. Apart, Table A.1, B.1 & B.2 are quite beneficial in narrowing down the choice of investors and identifying individual companies funding history.

SECTION A

12 Pages Infographics and Table, describes worldwide distribution of 321 Active Oncology Drug Funding Firms, with their country wise location, assets size, geographic investment preferences, ideal investment range and investment focus towards –early, mid and late stage funding.

SECTION B

33 Pages Infographics and Tables, provides the complete insights of oncology funding pattern in past 10 years in 449 cancer focused companies, with geographic emphasis on investments in Exit (through IPO/M&A) and Active companies. Navigation tables for Exit and Active companies to provide list of all major funding rounds and their investors.

SECTION C

502 Pages contain 321 active oncology focused investor firms profiles covering details of contact, Funds under management, Total investment portfolio Vs. cancer focused investment portfolio, geographic investment preference and investment range.

Individual Firm management profiles of key oncology focused venture partners, e-mail/LinkedIn contact details. Firm's all major oncology focused investments, series/rounds details with list of co-investors.



How this Report can Help

CXOs / Directors / VPs

- First innovative report to provide insights on several new strategic/financial investors willing to fund your company's growth.
- Identify key venture partners contribution and strategic positions on Company's Board.
- Detailed series co-investors details to identify best investors consortium for your needs.
- Access to Numerous deals, structure & size to analyze true value of business model.

Venture Partners

- Identify new emerging players in drug funding, with their core team and funding preferences.
- De-risk the venture by getting real insights through a comprehensive picture.
- Infographics design with focused and interactive content, takes no time in filling knowledge gaps.
- Virtually cover all oncology focused funding deals occurs in past 10 years with their valuation sizes.

Start-ups / Entrepreneurs

- Clearly identify - who will invest in your business and to which extent.
- Quickly navigate the complete profiles of focused Investors and their investment strategies.
- Identify the extent of funding in each round/series to meet your immediate and future needs.
- To design and negotiate on better financial plans to unlock the real value of innovation/assets.
- Directly get in touch with oncology focused Venture Partner through LinkedIn & E-mail ID.

Analysts/ Consultants

- Explore Top Investors and eliminate your hours of digital search and data curation.
- Spend quality time in analyzing finer funding details & decisions making.
- Identify paradigm shift in oncology drug funding; with 10 years of funding history covering 500+ companies and 3000+ Deals.
- Closely monitor wining deals and M&A activities by bringing more data under analysis.

*A Perfect Guide to provide complete
Landscape on Oncology Drug Funding.*

